Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pangu BioPharma
Hong Kong, Hong Kong, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Pangu BioPharma is a Hong Kong–based subsidiary of aTyr Pharma that supports basic and translational research into extracellular tRNA synthetase biology and Neuropilin-2–targeting bispecific antibodies; its work contributed to the discovery of aTyr’s clinical-stage fusion protein efzofitimod (ATYR1923) for interstitial lung diseases, but Pangu itself does not sponsor independent clinical trials.
- Therapeutic areas
- OncologyImmunologyPulmonology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyRecombinant fusion proteinProtein
- Industry
- Drug Discovery Services
02
Partnerships
The Hong Kong University of Science and Technology (HKUST)Hong Kong Government Innovation and Technology Commission (ITC)
Beyond the preview
Go deeper on Pangu BioPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pangu BioPharma.